$BIOLQ
BIOLASE, INC

2020 Form 10-K Financial Statement

#000156459021017121 Filed on March 31, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $22.78M $10.18M $37.80M
YoY Change -39.73% -21.99% -18.1%
Cost Of Revenue $16.61M $5.770M $23.51M
YoY Change -29.36% -22.34% -19.65%
Gross Profit $6.173M $4.420M $14.29M
YoY Change -56.8% -21.21% -15.43%
Gross Profit Margin 27.1% 43.42% 37.8%
Selling, General & Admin $21.01M $6.370M $25.14M
YoY Change -16.43% -21.94% -15.88%
% of Gross Profit 340.42% 144.12% 175.98%
Research & Development $3.695M $1.100M $4.765M
YoY Change -22.46% -14.06% -8.42%
% of Gross Profit 59.86% 24.89% 33.35%
Depreciation & Amortization $499.0K $230.0K $982.0K
YoY Change -49.19% -4.17% 3.92%
% of Gross Profit 8.08% 5.2% 6.87%
Operating Expenses $24.71M $7.460M $29.91M
YoY Change -17.39% -20.97% -20.83%
Operating Profit -$18.50M -$3.040M -$15.60M
YoY Change 18.59% -20.63% -25.31%
Interest Expense $2.359M -$650.0K $2.157M
YoY Change 9.36% 47.73% -478.42%
% of Operating Profit
Other Income/Expense, Net -$1.835M $2.278M
YoY Change -180.55%
Pretax Income -$16.70M -$3.700M -$17.90M
YoY Change -6.69% -46.76% -16.55%
Income Tax $128.0K -$110.0K -$44.00K
% Of Pretax Income
Net Earnings -$16.83M -$3.590M -$17.86M
YoY Change -5.75% -48.12% -17.02%
Net Earnings / Revenue -73.88% -35.27% -47.24%
Basic Earnings Per Share -$0.56 -$0.77
Diluted Earnings Per Share -$0.56 -$127.4K -$0.77
COMMON SHARES
Basic Shares Outstanding 61.14M 23.20M
Diluted Shares Outstanding 61.14M 23.20M

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.56M $5.790M $5.790M
YoY Change 203.28% -27.99% -27.99%
Cash & Equivalents $17.56M $5.789M $5.790M
Short-Term Investments
Other Short-Term Assets $3.330M $364.0K $1.470M
YoY Change 126.53% -80.84% -22.63%
Inventory $11.16M $11.00M $11.00M
Prepaid Expenses
Receivables $3.060M $8.760M $8.760M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $35.11M $27.02M $27.02M
YoY Change 29.94% -18.88% -18.88%
LONG-TERM ASSETS
Property, Plant & Equipment $2.760M $1.193M $1.470M
YoY Change 87.76% -39.59% -25.76%
Goodwill $2.926M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $230.0K $433.0K $430.0K
YoY Change -46.51% 40.58% 38.71%
Total Long-Term Assets $5.920M $4.828M $4.830M
YoY Change 22.57% -7.31% -7.29%
TOTAL ASSETS
Total Short-Term Assets $35.11M $27.02M $27.02M
Total Long-Term Assets $5.920M $4.828M $4.830M
Total Assets $41.03M $31.85M $31.85M
YoY Change 28.82% -17.31% -17.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.650M $5.332M $5.330M
YoY Change -50.28% -10.43% -10.42%
Accrued Expenses $5.770M $4.744M $3.790M
YoY Change 52.24% -37.07% -38.17%
Deferred Revenue $2.237M
YoY Change -9.65%
Short-Term Debt $0.00 $13.47M $13.47M
YoY Change -100.0%
Long-Term Debt Due $13.47M
YoY Change
Total Short-Term Liabilities $11.22M $25.78M $25.78M
YoY Change -56.48% 61.45% 61.43%
LONG-TERM LIABILITIES
Long-Term Debt $16.19M $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $3.590M $1.119M $1.650M
YoY Change 117.58% 1019.0% 200.0%
Total Long-Term Liabilities $19.78M $1.119M $1.650M
YoY Change 1098.79% -89.77% -85.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.22M $25.78M $25.78M
Total Long-Term Liabilities $19.78M $1.119M $1.650M
Total Liabilities $31.00M $27.51M $27.51M
YoY Change 12.69% 0.28% 0.29%
SHAREHOLDERS EQUITY
Retained Earnings -$234.5M
YoY Change 8.24%
Common Stock $235.6M
YoY Change 3.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.03M $377.0K $4.340M
YoY Change
Total Liabilities & Shareholders Equity $41.03M $31.85M $31.85M
YoY Change 28.82% -17.31% -17.32%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$16.83M -$3.590M -$17.86M
YoY Change -5.75% -48.12% -17.02%
Depreciation, Depletion And Amortization $499.0K $230.0K $982.0K
YoY Change -49.19% -4.17% 3.92%
Cash From Operating Activities -$12.80M -$4.680M -$12.75M
YoY Change 0.38% 31.46% -9.9%
INVESTING ACTIVITIES
Capital Expenditures $96.00K -$70.00K $207.0K
YoY Change -53.62% -84.44% -62.9%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$96.00K -$70.00K -$207.0K
YoY Change -53.62% -84.44% -60.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.171M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.35M 8.300M 10.72M
YoY Change 127.12% -17.08% -4.57%
NET CHANGE
Cash From Operating Activities -12.80M -4.680M -12.75M
Cash From Investing Activities -96.00K -70.00K -207.0K
Cash From Financing Activities 24.35M 8.300M 10.72M
Net Change In Cash 11.78M 3.550M -2.255M
YoY Change -622.17% -40.83% -36.3%
FREE CASH FLOW
Cash From Operating Activities -$12.80M -$4.680M -$12.75M
Capital Expenditures $96.00K -$70.00K $207.0K
Free Cash Flow -$12.89M -$4.610M -$12.95M
YoY Change -0.48% 48.23% -11.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity File Number
EntityFileNumber
001-36385
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
149379876
CY2020Q2 dei Entity Public Float
EntityPublicFloat
22577920
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
CY2020 dei City Area Code
CityAreaCode
949
CY2020 dei Local Phone Number
LocalPhoneNumber
361-1200
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17564000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5789000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3059000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8760000
CY2020Q4 us-gaap Inventory Net
InventoryNet
11157000
CY2019Q4 us-gaap Inventory Net
InventoryNet
10995000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3018000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1163000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35110000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
27019000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
782000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1193000
CY2020Q4 us-gaap Goodwill
Goodwill
2926000
CY2019Q4 us-gaap Goodwill
Goodwill
2926000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1976000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
276000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
433000
CY2020Q4 us-gaap Assets
Assets
41025000
CY2019Q4 us-gaap Assets
Assets
31847000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2651000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5332000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6667000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4744000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1905000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2237000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
13466000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11223000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25779000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
374000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
358000
CY2020Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
384000
CY2019Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
245000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1774000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1056000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1119000
CY2020Q4 us-gaap Liabilities
Liabilities
30997000
CY2019Q4 us-gaap Liabilities
Liabilities
27505000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
3965000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
118000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
98000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
261573000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235594000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-385000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-701000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251376000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-234547000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10028000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
377000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41025000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31847000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4017000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2531000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97708502
CY2018 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
12000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31439000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97663419
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31439000
CY2020 biol Products And Services Revenue
ProductsAndServicesRevenue
22780000
CY2019 biol Products And Services Revenue
ProductsAndServicesRevenue
37787000
CY2018 biol Products And Services Revenue
ProductsAndServicesRevenue
46143000
CY2019 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
12000
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
70000
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
70000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
18000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
18000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22780000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37799000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46155000
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
16607000
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
23511000
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
29260000
CY2020 us-gaap Gross Profit
GrossProfit
6173000
CY2019 us-gaap Gross Profit
GrossProfit
14288000
CY2018 us-gaap Gross Profit
GrossProfit
16895000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11242000
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14396000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18121000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9772000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10748000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11771000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4765000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5203000
CY2018 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-1185000
CY2018 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-1500000
CY2020 us-gaap Operating Expenses
OperatingExpenses
24709000
CY2019 us-gaap Operating Expenses
OperatingExpenses
29909000
CY2018 us-gaap Operating Expenses
OperatingExpenses
37780000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-15621000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-20885000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-58000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1835000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16701000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17899000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
128000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-44000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
63000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-16829000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-17855000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-21516000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
316000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-31000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-94000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16513000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17886000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21610000
CY2020 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
17378000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34207000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17855000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21516000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61136000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23201000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20588000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61136000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23201000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20588000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
29260000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2018 biol Adjustments To Additional Paid In Capital Fees For Rights Offering
AdjustmentsToAdditionalPaidInCapitalFeesForRightsOffering
38000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2627000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
847000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11089000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4250000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
364000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
161000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3798000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
856000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
67000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2591000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
163000
CY2020 biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
1544000
CY2020 us-gaap Profit Loss
ProfitLoss
-16829000
CY2019 us-gaap Profit Loss
ProfitLoss
-17855000
CY2019 biol Earned Interest Income
EarnedInterestIncome
-2000
CY2018 biol Earned Interest Income
EarnedInterestIncome
-1000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4286000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-655000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1458000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
871000
CY2018 us-gaap Profit Loss
ProfitLoss
-21516000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
499000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
982000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
945000
CY2018 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-1228000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1328000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1695000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
469000
CY2020 biol Provision For Sales Returns
ProvisionForSalesReturns
87000
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
-591000
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
413000
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
166000
CY2020 biol Inventory Write Offs And Disposals
InventoryWriteOffsAndDisposals
-1300000
CY2019 biol Inventory Write Offs And Disposals
InventoryWriteOffsAndDisposals
-15000
CY2018 biol Inventory Write Offs And Disposals
InventoryWriteOffsAndDisposals
-128000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
165000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
140000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
202000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
331000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
188000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
126000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5850000
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1641000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3370000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2742000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2768000
CY2019 biol Gain Loss On Issuance Of Warrants To Consultants
GainLossOnIssuanceOfWarrantsToConsultants
-48000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
7000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-27000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-825000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
255000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-825000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-439000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
25000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2107000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3156000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1762000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-379000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
114000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-161000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12795000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12746000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14147000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
96000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
207000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
558000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
36000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-96000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-207000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-522000
CY2020 biol Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
6912000
CY2020 biol Principal Payment On Term Loan
PrincipalPaymentOnTermLoan
700000
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
3000000
CY2019 biol Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
9171000
CY2020 biol Proceeds From Sale Of Preferred Stock
ProceedsFromSaleOfPreferredStock
2700000
CY2020 biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
15300000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1281000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
821000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
164000
CY2020 biol Payments Of Warrant Issuance Costs In Financing Activities
PaymentsOfWarrantIssuanceCostsInFinancingActivities
1640000
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
46000
CY2020 us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
3140000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2500000
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
12500000
CY2020 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
3000000
CY2018 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
3696000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
128000
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
133000
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1058000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
46000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24349000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10721000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11235000
CY2020 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
317000
CY2019 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-23000
CY2018 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-106000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11775000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2255000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3540000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6101000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8356000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11896000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17876000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1881000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1784000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
23000
CY2020 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
11000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
22000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
35000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
44000
CY2020 biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
489000
CY2019 biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
797000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
18000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000
CY2020 biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
151000
CY2019 biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
201000
CY2020 biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
2037000
CY2019 biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
276000
CY2020 biol Non Cash Equity Financing Costs In Accounts Payable
NonCashEquityFinancingCostsInAccountsPayable
74000
CY2019 biol Non Cash Equity Financing Costs In Accounts Payable
NonCashEquityFinancingCostsInAccountsPayable
129000
CY2020 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
17378000
CY2018 biol Non Cash Loss On Patent Litigation Settlement
NonCashLossOnPatentLitigationSettlement
1500000
CY2020 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
10000
CY2020 biol Receivable From Warrants Exercised And Included In Prepaid And Other Current Assets
ReceivableFromWarrantsExercisedAndIncludedInPrepaidAndOtherCurrentAssets
1498000
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
67000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
161000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
847000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.27%;text-indent:1.9%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:1.9%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the years ended December&#160;31, 2020, 2019, and 2018, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may affect the price competitiveness of the Company&#8217;s products outside the U.S.</p>
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
24000000
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
24000000
CY2021Q1 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
14400000
CY2020 us-gaap Depreciation
Depreciation
500000
CY2019 us-gaap Depreciation
Depreciation
1000000
CY2018 us-gaap Depreciation
Depreciation
900000
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2018 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1200000
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.81
CY2019 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.81
CY2018 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.86
CY2020 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.19
CY2019 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.19
CY2018 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.14
CY2020Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
670000
CY2019Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
559000
CY2020Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1609000
CY2019Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2063000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2279000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2622000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
374000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
385000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1905000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2237000
CY2020 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
300000
CY2019 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
500000
CY2020 biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
2000000
CY2019 biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
2100000
CY2020 biol Contract With Customer Liability Revenue Recognized Deferred Royalties
ContractWithCustomerLiabilityRevenueRecognizedDeferredRoyalties
0
CY2019 biol Contract With Customer Liability Revenue Recognized Deferred Royalties
ContractWithCustomerLiabilityRevenueRecognizedDeferredRoyalties
0
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1110000
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1308000
CY2020 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1047000
CY2019 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
806000
CY2018 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
901000
CY2020 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1025000
CY2019 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1004000
CY2018 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
783000
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1132000
CY2018Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
447000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
748000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
865000
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
861000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
600000
CY2019 us-gaap Advertising Expense
AdvertisingExpense
500000
CY2018 us-gaap Advertising Expense
AdvertisingExpense
600000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3370000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2742000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2768000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1000000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M3D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M13D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.03
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.85
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.81
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0037
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0255
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0254
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56035000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53222000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
61122000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6922000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5862000
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
3059000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
8760000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
4000000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2500000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3721000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3689000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1158000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1064000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6278000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6242000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
800000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1300000
CY2020 biol Write Downs For Excess And Obsolete Inventory Expense
WriteDownsForExcessAndObsoleteInventoryExpense
1300000
CY2019 biol Write Downs For Excess And Obsolete Inventory Expense
WriteDownsForExcessAndObsoleteInventoryExpense
15000
CY2018 biol Write Downs For Excess And Obsolete Inventory Expense
WriteDownsForExcessAndObsoleteInventoryExpense
100000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
947000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
799000
CY2020Q4 biol Receivable For Warrants Exercised
ReceivableForWarrantsExercised
1498000
CY2019Q4 biol Receivable For Warrants Exercised
ReceivableForWarrantsExercised
0
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
573000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
364000
CY2020Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8269000
CY2019Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10353000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7664000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9322000
CY2020Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
605000
CY2019Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1031000
CY2020Q4 us-gaap Land
Land
177000
CY2019Q4 us-gaap Land
Land
162000
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3552000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1726000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
165000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
242000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
281000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
330000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
885000
CY2019Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
546000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
305000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
323000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
731000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
712000
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2800000
CY2020 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
indefinite life
CY2020Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
26000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
23000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
14000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
101000
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
73000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
90000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
127000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
96000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
104000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-12000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-41000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
1000
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-128000
CY2020 biol Deferred Income Tax Expense Benefit Adjustment
DeferredIncomeTaxExpenseBenefitAdjustment
1000
CY2019 biol Deferred Income Tax Expense Benefit Adjustment
DeferredIncomeTaxExpenseBenefitAdjustment
-140000
CY2018 biol Deferred Income Tax Expense Benefit Adjustment
DeferredIncomeTaxExpenseBenefitAdjustment
-41000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.161
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.350
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.286
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.048
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.070
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.031
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.006
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.021
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.017
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.041
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.024
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.097
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.200
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.005
CY2020 biol Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards
EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards
-0.037
CY2019 biol Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards
EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards
-0.107
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.006
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.026
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.033
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.004
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
-38000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
-38000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
2094000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1384000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
139000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
44000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4813000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4694000
CY2020Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
3000
CY2019Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
5000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3333000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3429000
CY2020Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
858000
CY2019Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
974000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
166000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
302000
CY2020Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
105000
CY2019Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
111000
CY2020Q4 biol Deferred Tax Assets Disallowed Interest
DeferredTaxAssetsDisallowedInterest
1128000
CY2019Q4 biol Deferred Tax Assets Disallowed Interest
DeferredTaxAssetsDisallowedInterest
708000
CY2020Q4 biol Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
518000
CY2019Q4 biol Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
129000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44345000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42527000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57464000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54269000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1429000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1047000
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
664000
CY2019Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
708000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
492000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
109000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
221000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
179000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1377000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
996000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
52000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
51000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
179100000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
110100000
CY2020 biol Operating Loss Carryforwards Expirations Period
OperatingLossCarryforwardsExpirationsPeriod
2022
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2018 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
59000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
509000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2019 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
509000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
509000
CY2020 biol Current Inome Related To Global Intangible Low Taxed Income
CurrentInomeRelatedToGlobalIntangibleLowTaxedIncome
15000000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16186000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
13466000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5080000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2803000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
9403000
CY2020Q4 biol Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
143000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
17429000
CY2020Q4 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
1795000
CY2020Q4 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
1760000
CY2020Q4 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
1390000
CY2020Q4 biol Long Term Debt Maturities Repayments Of Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearFour
1896000
CY2020Q4 biol Long Term Debt Maturities Repayments Of Interest In Year After Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFour
81000
CY2020Q4 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
6922000
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q4 biol Lease Facility Area
LeaseFacilityArea
11000
CY2020 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-12-31
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1278
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P66M
CY2020Q1 biol Lease Facility Area
LeaseFacilityArea
11000
CY2020Q1 biol Lease Facility Area
LeaseFacilityArea
11000
CY2020Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-07-01
CY2020Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-07-01
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
489000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
797000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1976000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
803000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128
CY2020 us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
As of December 31, 2020, the Company had no leases that had not commenced.
CY2020 biol Lessee Operating Lease Number Of Lease Not Yet Commenced
LesseeOperatingLeaseNumberOfLeaseNotYetCommenced
0
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
549000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
573000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
587000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
587000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
489000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2785000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
706000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2079000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
326000
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2020Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
11400000
CY2019Q4 biol Proceeds From Common Stock Offering And Concurrent Private Placement
ProceedsFromCommonStockOfferingAndConcurrentPrivatePlacement
8200000
CY2020 biol Dividend Declared
DividendDeclared
0
CY2019 biol Dividend Declared
DividendDeclared
0
CY2018 biol Dividend Declared
DividendDeclared
0
CY2020Q2 biol Other Offering Expenses
OtherOfferingExpenses
700000
CY2019Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.5750
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1347000
CY2018 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
611000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
334000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1623000
CY2019 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
90000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
424000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1287000
CY2020 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
1258000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
147000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2398000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1074000
CY2020 biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
17
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.99
CY2018 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
1.98
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.10
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.68
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.54
CY2019 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
1.74
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.10
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.43
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.77
CY2020 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
0.38
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.87
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.29
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.51
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.38
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
227000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
587000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1191000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.96
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.05
CY2020 biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.20
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53000
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2398000
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.96
CY2020 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1074000
CY2020Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
6.05
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1975000

Files In Submission

Name View Source Status
0001564590-21-017121-index-headers.html Edgar Link pending
0001564590-21-017121-index.html Edgar Link pending
0001564590-21-017121.txt Edgar Link pending
0001564590-21-017121-xbrl.zip Edgar Link pending
biol-10k_20201231.htm Edgar Link pending
biol-20201231.xml Edgar Link completed
biol-20201231.xsd Edgar Link pending
biol-20201231_cal.xml Edgar Link unprocessable
biol-20201231_def.xml Edgar Link unprocessable
biol-20201231_lab.xml Edgar Link unprocessable
biol-20201231_pre.xml Edgar Link unprocessable
biol-ex1041_244.htm Edgar Link pending
biol-ex1044_243.htm Edgar Link pending
biol-ex211_12.htm Edgar Link pending
biol-ex231_10.htm Edgar Link pending
biol-ex311_6.htm Edgar Link pending
biol-ex321_13.htm Edgar Link pending
biol-ex413_574.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending